Infectious Disease Special Edition news story
The investigational antibiotic TBD09 could have the potential to treat TB with less toxicity, according to new research.
The preclinical study, published in Nature Medicine, shows that TBD09, also called MK-7762, had strong efficacy in animal models with a favorable safety profile. These results, and favorable phase 1 data, indicate TBD09 may hold promise for TB.
TBD09 is an oxazolidinone, the same class as linezolid.
Read the full news story here.
For more TB updates, check out the TB CAB Weekly Newsletter (Issue #4, 1 February 2026).
The newsletter is brought to you by the Global TB Community Advisory Board (TB CAB) with the support of Treatment Action Group (TAG) and the European AIDS Treatment Group (EATG). Subscribe to the newsletter here.
Source : Infectious Disease Special Edition
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.